EP1563068 - GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND THE USE THEREOF [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 01.03.2019 Database last updated on 31.08.2024 | |
Former | The patent has been granted Status updated on 23.03.2018 | ||
Former | Grant of patent is intended Status updated on 06.07.2017 | ||
Former | Examination is in progress Status updated on 09.11.2016 | Most recent event Tooltip | 03.07.2020 | Lapse of the patent in a contracting state New state(s): CY | published on 05.08.2020 [2020/32] | Applicant(s) | For all designated states Astellas Pharma Inc. 5-1, Nihonbashi-Honcho 2-chome Chuo-ku Tokyo 103-8411 / JP | [2018/30] |
Former [2018/29] | For all designated states Ganymed Pharmaceuticals GmbH An der Goldgrube 12 55131 Mainz / DE | ||
Former [2015/23] | For all designated states Ganymed Pharmaceuticals AG An der Goldgrube 12 55131 Mainz / DE | ||
Former [2005/33] | For all designated states Ganymed Pharmaceuticals AG Freiligrathstr. 12 55131 Mainz / DE | Inventor(s) | 01 /
SAHIN, Ugur Philipp von Zabern Platz 1 55116 Mainz / DE | 02 /
TÜRECI, Özlem Philipp von Zabern Platz 1 55116 Mainz / DE | 03 /
KOSLOWSKI, Michael Autogenstrasse 50 65933 Frankfurt / DE | [2010/39] |
Former [2007/12] | 01 /
SAHIN, Ugur Philipp von Zabern Platz 1 55116 Mainz / DE | ||
02 /
TÜRECI, Özlem Philipp von Zabern Platz 1 55116 Mainz / DE | |||
03 /
KOSLOWSKI, Michael Kaiserstrasse 72 55116 Mainz / DE | |||
Former [2005/33] | 01 /
SAHIN, Ugur Philipp von Zabern Platz 1 55116 Mainz / DE | ||
02 /
TÜRECI, Özlem Philipp von Zabern Platz 1 55116 Mainz / DE | |||
03 /
KOSLOWSKI, Michael Rodderweg 24 50999 Köln / DE | Representative(s) | Schnappauf, Georg, et al ZSP Patentanwälte PartG mbB Hansastraße 32 80686 München / DE | [2018/17] |
Former [2005/33] | Schnappauf, Georg Dr., et al Dr. Volker Vossius Patent- und Rechtsanwaltskanzlei Geibelstrasse 6 81679 München / DE | Application number, filing date | 03773719.4 | 21.11.2003 | [2005/33] | WO2003EP13091 | Priority number, date | DE20021054601 | 22.11.2002 Original published format: DE 10254601 | [2005/33] | Filing language | DE | Procedural language | DE | Publication | Type: | A2 Application without search report | No.: | WO2004047863 | Date: | 10.06.2004 | Language: | DE | [2004/24] | Type: | A2 Application without search report | No.: | EP1563068 | Date: | 17.08.2005 | Language: | DE | The application published by WIPO in one of the EPO official languages on 10.06.2004 takes the place of the publication of the European patent application. | [2005/33] | Type: | B1 Patent specification | No.: | EP1563068 | Date: | 25.04.2018 | Language: | DE | [2018/17] | Search report(s) | International search report - published on: | EP | 06.01.2005 | Classification | IPC: | C07K16/18, C07K16/30, G01N33/574, A61K39/395, C07K14/47 | [2015/51] | CPC: |
C07K14/47 (EP,CN,KR,US);
A61K39/39558 (KR);
A61K48/005 (CN);
C07K16/3076 (US);
A61K39/0011 (CN);
A61K39/395 (CN);
A61K47/549 (US);
A61P1/04 (EP);
A61P1/18 (EP);
A61P11/00 (EP);
A61P13/08 (EP);
A61P13/12 (EP);
A61P15/00 (EP);
A61P17/00 (EP);
A61P35/00 (EP,KR);
A61P43/00 (EP);
C07K16/18 (EP,CN,KR,US);
C07K16/30 (EP,KR,US);
C07K16/3023 (EP,US);
C07K16/3046 (EP,US);
C12Q1/6886 (CN);
G01N33/5011 (CN);
G01N33/5017 (CN);
G01N33/57407 (CN);
G01N33/57484 (EP,CN,US);
A61K2039/505 (EP,KR,US);
C07K2317/30 (KR,US);
C07K2317/34 (EP,KR,US);
C12N2503/02 (CN);
C12Q2600/136 (CN);
|
Former IPC [2005/33] | C12N15/11 | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR [2018/17] |
Former [2005/33] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR | Extension states | AL | 28.04.2005 | LT | 28.04.2005 | LV | 28.04.2005 | MK | 28.04.2005 | Title | German: | IN TUMOREN DIFFERENTIELL EXPRIMIERTE GENPRODUKTE UND DEREN VERWENDUNG | [2005/33] | English: | GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND THE USE THEREOF | [2005/33] | French: | PRODUITS GENIQUES EXPRIMES DE MANIERE DIFFERENTIELLE DANS DES TUMEURS ET LEUR UTILISATION | [2005/33] | Entry into regional phase | 28.04.2005 | National basic fee paid | 28.04.2005 | Designation fee(s) paid | 28.04.2005 | Examination fee paid | Examination procedure | 28.04.2005 | Examination requested [2005/33] | 29.07.2005 | Amendment by applicant (claims and/or description) | 08.09.2009 | Despatch of a communication from the examining division (Time limit: M04) | 08.09.2009 | Invitation to provide information on prior art | 18.01.2010 | Reply to a communication from the examining division | 18.01.2010 | Reply to the invitation to provide information on prior art | 09.03.2012 | Despatch of a communication from the examining division (Time limit: M06) | 06.09.2012 | Reply to a communication from the examining division | 07.10.2013 | Despatch of a communication from the examining division (Time limit: M06) | 10.04.2014 | Reply to a communication from the examining division | 09.11.2015 | Cancellation of oral proceeding that was planned for 11.11.2015 | 11.11.2015 | Date of oral proceedings (cancelled) | 04.01.2016 | Communication of intention to grant the patent | 02.02.2016 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 22.03.2016 | Communication of intention to grant the patent | 27.10.2016 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 13.06.2017 | Date of oral proceedings | 06.07.2017 | Minutes of oral proceedings despatched | 07.07.2017 | Communication of intention to grant the patent | 03.01.2018 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time | 13.03.2018 | Fee for grant paid | 13.03.2018 | Fee for publishing/printing paid | 13.03.2018 | Receipt of the translation of the claim(s) | Divisional application(s) | EP11007306.1 / EP2399995 | EP11007307.9 / EP2399996 | EP11007308.7 / EP2399997 | EP11007309.5 / EP2399998 | EP11007310.3 / EP2399999 | EP11007311.1 / EP2400000 | EP11007312.9 / EP2400001 | EP11007313.7 / EP2400002 | EP11007314.5 / EP2400003 | EP11007315.2 / EP2400004 | EP11007316.0 / EP2400005 | EP11007317.8 / EP2400006 | EP11007318.6 / EP2400007 | EP11007319.4 / EP2400008 | EP11007320.2 / EP2400009 | EP11007321.0 / EP2400010 | EP11007322.8 / EP2400011 | EP11007323.6 / EP2400012 | EP11007324.4 / EP2400013 | EP11007325.1 / EP2400014 | EP11007326.9 / EP2400015 | EP11007327.7 / EP2400016 | EP11007328.5 / EP2400017 | EP11007329.3 / EP2400018 | EP11007330.1 / EP2400019 | EP18157559.8 / EP3348570 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 08.09.2009 | Opposition(s) | 28.01.2019 | No opposition filed within time limit [2019/14] | Request for further processing for: | The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent | 13.03.2018 | Request for further processing filed | 13.03.2018 | Full payment received (date of receipt of payment) Request granted | 26.03.2018 | Decision despatched | The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent | 27.10.2016 | Request for further processing filed | 27.10.2016 | Full payment received (date of receipt of payment) Request granted | 10.11.2016 | Decision despatched | Fees paid | Renewal fee | 14.11.2005 | Renewal fee patent year 03 | 14.11.2006 | Renewal fee patent year 04 | 30.11.2007 | Renewal fee patent year 05 | 31.10.2008 | Renewal fee patent year 06 | 27.10.2009 | Renewal fee patent year 07 | 25.11.2010 | Renewal fee patent year 08 | 28.11.2011 | Renewal fee patent year 09 | 28.11.2012 | Renewal fee patent year 10 | 29.11.2013 | Renewal fee patent year 11 | 27.11.2014 | Renewal fee patent year 12 | 27.11.2015 | Renewal fee patent year 13 | 29.11.2016 | Renewal fee patent year 14 | 30.11.2017 | Renewal fee patent year 15 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 21.11.2003 | CY | 25.04.2018 | CZ | 25.04.2018 | DK | 25.04.2018 | EE | 25.04.2018 | FI | 25.04.2018 | MC | 25.04.2018 | NL | 25.04.2018 | RO | 25.04.2018 | SE | 25.04.2018 | SI | 25.04.2018 | SK | 25.04.2018 | TR | 25.04.2018 | BG | 25.07.2018 | GR | 26.07.2018 | PT | 27.08.2018 | AT | 21.11.2018 | IE | 21.11.2018 | LU | 21.11.2018 | BE | 30.11.2018 | [2020/32] |
Former [2020/30] | HU | 21.11.2003 | |
CZ | 25.04.2018 | ||
DK | 25.04.2018 | ||
EE | 25.04.2018 | ||
FI | 25.04.2018 | ||
MC | 25.04.2018 | ||
NL | 25.04.2018 | ||
RO | 25.04.2018 | ||
SE | 25.04.2018 | ||
SI | 25.04.2018 | ||
SK | 25.04.2018 | ||
TR | 25.04.2018 | ||
BG | 25.07.2018 | ||
GR | 26.07.2018 | ||
PT | 27.08.2018 | ||
AT | 21.11.2018 | ||
IE | 21.11.2018 | ||
LU | 21.11.2018 | ||
BE | 30.11.2018 | ||
Former [2020/16] | CZ | 25.04.2018 | |
DK | 25.04.2018 | ||
EE | 25.04.2018 | ||
FI | 25.04.2018 | ||
MC | 25.04.2018 | ||
NL | 25.04.2018 | ||
RO | 25.04.2018 | ||
SE | 25.04.2018 | ||
SI | 25.04.2018 | ||
SK | 25.04.2018 | ||
TR | 25.04.2018 | ||
BG | 25.07.2018 | ||
GR | 26.07.2018 | ||
PT | 27.08.2018 | ||
AT | 21.11.2018 | ||
IE | 21.11.2018 | ||
LU | 21.11.2018 | ||
BE | 30.11.2018 | ||
Former [2020/11] | CZ | 25.04.2018 | |
DK | 25.04.2018 | ||
EE | 25.04.2018 | ||
FI | 25.04.2018 | ||
MC | 25.04.2018 | ||
NL | 25.04.2018 | ||
RO | 25.04.2018 | ||
SE | 25.04.2018 | ||
SI | 25.04.2018 | ||
SK | 25.04.2018 | ||
BG | 25.07.2018 | ||
GR | 26.07.2018 | ||
PT | 27.08.2018 | ||
AT | 21.11.2018 | ||
IE | 21.11.2018 | ||
LU | 21.11.2018 | ||
BE | 30.11.2018 | ||
Former [2019/51] | CZ | 25.04.2018 | |
DK | 25.04.2018 | ||
EE | 25.04.2018 | ||
FI | 25.04.2018 | ||
MC | 25.04.2018 | ||
NL | 25.04.2018 | ||
RO | 25.04.2018 | ||
SE | 25.04.2018 | ||
SI | 25.04.2018 | ||
SK | 25.04.2018 | ||
BG | 25.07.2018 | ||
GR | 26.07.2018 | ||
PT | 27.08.2018 | ||
IE | 21.11.2018 | ||
LU | 21.11.2018 | ||
BE | 30.11.2018 | ||
Former [2019/48] | CZ | 25.04.2018 | |
DK | 25.04.2018 | ||
EE | 25.04.2018 | ||
FI | 25.04.2018 | ||
MC | 25.04.2018 | ||
NL | 25.04.2018 | ||
RO | 25.04.2018 | ||
SE | 25.04.2018 | ||
SI | 25.04.2018 | ||
SK | 25.04.2018 | ||
BG | 25.07.2018 | ||
GR | 26.07.2018 | ||
PT | 27.08.2018 | ||
IE | 21.11.2018 | ||
LU | 21.11.2018 | ||
Former [2019/34] | CZ | 25.04.2018 | |
DK | 25.04.2018 | ||
EE | 25.04.2018 | ||
FI | 25.04.2018 | ||
MC | 25.04.2018 | ||
NL | 25.04.2018 | ||
RO | 25.04.2018 | ||
SE | 25.04.2018 | ||
SI | 25.04.2018 | ||
SK | 25.04.2018 | ||
BG | 25.07.2018 | ||
GR | 26.07.2018 | ||
PT | 27.08.2018 | ||
LU | 21.11.2018 | ||
Former [2019/33] | CZ | 25.04.2018 | |
DK | 25.04.2018 | ||
EE | 25.04.2018 | ||
FI | 25.04.2018 | ||
MC | 25.04.2018 | ||
NL | 25.04.2018 | ||
RO | 25.04.2018 | ||
SE | 25.04.2018 | ||
SI | 25.04.2018 | ||
SK | 25.04.2018 | ||
BG | 25.07.2018 | ||
GR | 26.07.2018 | ||
PT | 27.08.2018 | ||
Former [2019/26] | CZ | 25.04.2018 | |
DK | 25.04.2018 | ||
EE | 25.04.2018 | ||
FI | 25.04.2018 | ||
NL | 25.04.2018 | ||
RO | 25.04.2018 | ||
SE | 25.04.2018 | ||
SI | 25.04.2018 | ||
SK | 25.04.2018 | ||
BG | 25.07.2018 | ||
GR | 26.07.2018 | ||
PT | 27.08.2018 | ||
Former [2019/10] | CZ | 25.04.2018 | |
DK | 25.04.2018 | ||
EE | 25.04.2018 | ||
FI | 25.04.2018 | ||
NL | 25.04.2018 | ||
RO | 25.04.2018 | ||
SE | 25.04.2018 | ||
SK | 25.04.2018 | ||
BG | 25.07.2018 | ||
GR | 26.07.2018 | ||
PT | 27.08.2018 | ||
Former [2019/09] | DK | 25.04.2018 | |
EE | 25.04.2018 | ||
FI | 25.04.2018 | ||
NL | 25.04.2018 | ||
SE | 25.04.2018 | ||
BG | 25.07.2018 | ||
GR | 26.07.2018 | ||
PT | 27.08.2018 | ||
Former [2019/08] | DK | 25.04.2018 | |
FI | 25.04.2018 | ||
NL | 25.04.2018 | ||
SE | 25.04.2018 | ||
BG | 25.07.2018 | ||
GR | 26.07.2018 | ||
PT | 27.08.2018 | ||
Former [2019/03] | FI | 25.04.2018 | |
NL | 25.04.2018 | ||
SE | 25.04.2018 | ||
BG | 25.07.2018 | ||
GR | 26.07.2018 | ||
PT | 27.08.2018 | ||
Former [2018/52] | FI | 25.04.2018 | |
NL | 25.04.2018 | ||
SE | 25.04.2018 | ||
BG | 25.07.2018 | ||
GR | 26.07.2018 | ||
Former [2018/49] | FI | 25.04.2018 | |
NL | 25.04.2018 | ||
SE | 25.04.2018 | ||
BG | 25.07.2018 | ||
Former [2018/47] | FI | 25.04.2018 | |
NL | 25.04.2018 | ||
Former [2018/43] | NL | 25.04.2018 | Cited in | International search | [XY]WO9964452 (SMITHKLINE BEECHAM CORP [US]) [X] 1-5,7-16,20-22,24-27,29,32-35,37-39,44,47-50,53,55-60,64,66,74-81,83,84,86-89,95,98 * the whole document * [Y] 1-72,74-81,83-98; | [Y]WO0127257 (UNIV ARKANSAS [US]) [Y] 1-72,74-81,83-98 * the whole document *; | [X]US6235481 (HORIKAWA YUKIO [JP], et al) [X] 74,80,81,83-85 * column 79, paragraph L - column 80, paragraph 1; example 4 *; | [Y]WO0162920 (CORIXA CORP [US]) [Y] 1-72,74-81,83-98 * the whole document *; | [Y]WO0175067 (HYSEQ INC [US], et al) [Y] 1-72,86-98 * abstract *; | [XY]WO0214500 (CHIRON CORP [US], et al) [X] 1-5,7-16,20-27,29-39,44,47-50,53,55-60,64,66,71,72,86-89,95,98 * abstract * * page 267 * * page 409 * * page 486 * * page 505 * * page 614 * * page 646 * * page 661 * * page 680 * * page 684 * [Y] 1-72,86-98,1-72,86-98; | [X]WO02061087 (LIFESPAN BIOSCIENCES INC [US], et al) [X] 74,75,83,84 * paragraph [0129] *; | [PX]WO02103028 (BIOMEDICAL CT [RU]) [PX] 74 * page 41, paragraph 8 *; | [Y] - BARANOVA^A A V ET AL, "In silico screening for tumour-specific expressed sequences in human genome", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, (20011109), vol. 508, no. 1, ISSN 0014-5793, pages 143 - 148, XP004322294 [Y] 1-72,74-81,83-98 * page 147, column L * * page 146, column R, paragraph L * * table 3 * DOI: http://dx.doi.org/10.1016/S0014-5793(01)03028-9 | [Y] - REITER Y ET AL, "peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, (199704), vol. 94, ISSN 0027-8424, pages 4631 - 4636, XP002967291 [Y] 90-94 * abstract * DOI: http://dx.doi.org/10.1073/pnas.94.9.4631 | [A] - O'DOWD B F ET AL, "Discovery of Three Novel G-Protein-Coupled Receptor Genes", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, (19980115), vol. 47, no. 2, ISSN 0888-7543, pages 310 - 313, XP004449298 [A] 1-98 * page 312, column L, paragraph 1 * DOI: http://dx.doi.org/10.1006/geno.1998.5095 | [Y] - ENGBERG J ET AL, "RECOMBINANT ANTIBODIES WITH THE ANTIGEN-SPECIFIC, MHC RESTRICTED SPECIFICITY OF T CELLS: NOVEL REAGENTS FOR BASIC AND CLINICAL INVESTIGATIONS AND IMMUNOTHERAPY", IMMUNOTECHNOLOGY, XX, XX, (199903), vol. 4, pages 273 - 278, XP000991083 [Y] 90-94 * abstract * DOI: http://dx.doi.org/10.1016/S1380-2933(98)00017-7 | [A] - KOSLOWSKI MICHAEL ET AL, "Multiple splice variants of lactate dehydrogenase C selectively expressed in human cancer", CANCER RESEARCH, (20021115), vol. 62, no. 22, ISSN 0008-5472, pages 6750 - 6755, XP002284383 [A] 1-72,74-81,83-98 * abstract * | Examination | WO0154708 | US2002119130 | - RIEMER A B ET AL, "Matching of trastuzumab (Herceptin<(>R)) epitope mimics onto the surface of Her-2/neu - a new method of epitope definition", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 42, no. 9, ISSN 0161-5890, (20050501), pages 1121 - 1124, (20050501), XP027635008 | - SAHIN UGUR ET AL, "Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20081201), vol. 14, no. 23, doi:10.1158/1078-0432.CCR-08-1547, ISSN 1078-0432, pages 7624 - 7634, XP002588324 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-08-1547 | - Y Sanada ET AL, "Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype", The Journal of Pathology, (20060401), vol. 208, no. 5, doi:10.1002/path.1922, ISSN 0022-3417, pages 633 - 642, XP055080460 DOI: http://dx.doi.org/10.1002/path.1922 | - P Büchler ET AL, "Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin)", Journal of Gastrointestinal Surgery, (20010401), vol. 5, no. 2, doi:10.1016/S1091-255X(01)80025-1, ISSN 1091-255X, pages 139 - 146, XP055188573 DOI: http://dx.doi.org/10.1016/S1091-255X(01)80025-1 |